Chaohong Fan (MD, PhD)

Dr. Fan is a lead oncology medical officer with 16-year-experience at Center of Biologics  Evaluation and Research (CBER) and Center of Drug Evaluation and Research (CDER) in the  U.S. Food and Drug Administration (FDA). Dr. Fan is responsible for conducting clinical  reviews and implementing regulations for cell and gene therapies for prevention, diagnosis, and  treatment of cancers at the Office of Tissues and Advanced Therapies (OTAT), CBER. This  office reviews, evaluates, and approves most innovative cancer therapeutics with curative  potential, including chimeric antigen receptor (CAR) T cells, adoptive T cell therapies, tumor  neoantigen-based personalized medicine, oncolytic viruses, therapeutic cancer vaccines, and  combinations of these immune-oncologic therapeutics with checkpoint inhibitors and other  agents. Dr. Fan is a board-certified medical oncologist and internist by American Board of  Internal Medicine (ABIM). She received an M.D. from Zunyi Medical College, Zunyi, China, a  M.Sc. in medical genetics from Hunan Medical University, Changsha in China, and a Ph.D. in  medical genetics from Umea University in Sweden. Prior to joining FDA, Dr. Fan conducted  researches in gene mapping and cloning for neurogenetic disorders, including Amyotrophic  Lateral Sclerosis (ALS, or Lou Gehrig’s Disease) at Northwestern University in Chicago. She is interested in clinical trial design and development of precision medicine and advanced therapies  in oncology.